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creativecommons.org/understand the importance of cerebrovascular biology in cognitive decline. Prevention and treatment
of VCID is poised to have major impact on dementia-related disease burden and is thus a critical
emerging objective in dementia research. This article presents VCID consortia focused on multidis-
ciplinary approaches to identify key pathologic targets and develop diagnostic tools with the goal of
bridging the divide between basic research and clinical trials. Members of these multi-institute, multi-
disciplinary consortia provide a prospective on the history and emerging science of VCID and how
VCID consortia can address some of themore complex questions in VCID and drive the field forward.
These consortia, and others like them, are uniquely suited to tackle some of the most difficult obsta-
cles in translating research to the clinic.
Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The science of vascular contributions to cognitive impair-
ment and dementia (VCID) seeks to understand the aging
neurovascular system when it fails to cope with biological
insults due to vascular disease, proteinopathy, metabolic dis-
ease, and immune affront, resulting in cognitive decline.
VCID takes many forms and occurs in the context of
numerous clinical diagnoses and comorbidities [1–3].thor. Tel.: 11 3014965680; Fax: 1 3014022060.
rdan.gladman@nih.gov
/j.trci.2019.09.017
by Elsevier Inc. on behalf of the Alzheimer’s Association
licenses/by-nc-nd/4.0/).In some of these conditions, the role of vascular disease is
evident, such as in dementia after stroke, whereas in
others, it is more covert as in insidious vascular damage
co-occurring with pathological Alzheimer’s disease (AD).
Importantly, it has become clear that vascular disease is pre-
sent in the majority of patients with dementia. It contributes
to the dementia phenotype to a large degree in some individ-
uals and to a smaller but still significant degree in others [4].
The impact of VCID is substantial. Because of the frequent
co-occurrence of other etiologies, it is not straightforward to
assess the exact population impact of VCID with existing
data. Nonetheless, it likely affects many millions of people
worldwide who are diagnosed with one of the vascular. This is an open access article under the CC BY-NC-ND license (http://
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nosis. Furthermore, based on our understanding of cardio-
vascular and cerebrovascular risk and observations of
dementia incidence, it is likely that there is disproportion-
ately high VCID burden among certain health disparity pop-
ulations [5,6]. Prevention and treatment of VCID is poised to
have a major impact and is thus a critical emerging objective
in dementia research [7–9].
VCID research integrates diverse fields of biology and
spans basic neuroscience, translational, and clinical
research. The extensive scope and overlapping diagnostic
and disciplinary boundaries of VCID has historically re-
sulted in relevant research being fragmented and siloed,
for example, among different forms of VCID and from other
dementia etiologies, and as a result, VCID has not until
recently been widely recognized as a potentially critical
contributor to the public burden of cognitive impairment
and dementia. Traditionally used concepts of vascular or
multi-infarct dementia have only captured a relatively nar-
row subset of VCID with multiple clinical strokes. Another
consideration that traditionally diminished the VCID
research footprint, relative to the actual disease burden, is
that VCID is infrequently called out diagnostically even
though it is present in the majority of cases, in particular
when the affected person is older than 80 years, which ac-
counts for the vast majority of dementia.
A bibliometric landscape analysis of VCID was
completed to identify trends in the production and research
topics of these publications using data from PubMed articles
from 2002 to 2018 (Fig. 1). Bibliometric methods are quan-
titative methods of studying scientific research using publi-
cations as a proxy for research. Although bibliometric
analysis has limitations, such as inability to interpret impact
or assess scientific rigor, this technique represents one
method to quantitatively evaluate the VCID field. This anal-
ysis highlights the multidisciplinary scientific nature of the
field, but also, underscores the vast and, at times, separated
nature of the research. However, there have been efforts to
enhance the field of VCID research by harmonizing termi-
nology, methodology and coming together to form multidis-
ciplinary research teams and consortia [10,11]. These groups
are well-positioned to address some of the more complex
questions in VCID.1.1. Perspective on the history and emerging science of
VCID
The development of highly specific and sensitive diag-
nostic criteria is a rigorous process that requires both strong
scientific evidence and adoption by the scientific and medi-
cal communities. At the same time, applied VCID research
depends on appropriate diagnostic criteria and biologically
valid, robust, sensitive, and specific markers of disease pro-
cesses. This must be balanced with the priority of ensuring a
diagnosis that will facilitate the best care of patients possiblewhile maintaining scientific interoperability that ensures
utility for clinicians and researchers. Achieving this has
been a challenge.
Initial diagnostic constructs strove to come up with defi-
nitions that would capture vascular disease as the sole cause
of cognitive impairment [12]. In accordance with the present
insights, this approach has important drawbacks, the most
prominent of which is that in the majority of patients with
cognitive impairment, vascular disease co-occurs with other
etiologies [4,13]. Excluding the other etiologies narrows the
field and ignores combined and synergistic effects.
Moreover, from a clinical perspective, it is questionable if
co-occurring etiologies can be reliably identified based on
clinical phenotypes, and if co-occurring etiologies can be
identified, is it scientifically or clinically appropriate to
exclude them? Over the past decades, we have seen evolu-
tion of diagnostic constructs for VCID from vascular as
the sole cause (VaD criteria) to encompassing shared etiol-
ogies [11,14]. Studies now show that a substantial proportion
of patients who are assumed to have Alzheimer’s pathology,
including early onset inherited forms, additionally have ev-
idence of vascular pathology.
Like for dementia and cancer, a second challenge in diag-
nostic constructs for VCID is the fact that “vascular” is an
umbrella term and as such cannot be considered as a specific
etiology that guides treatment. For example, mechanisms,
diagnosis, and treatment of VCID in a patient with lasting
cognitive deficits after an acute subarachnoid hemorrhage
are evidently completely different from those in a patient
with progressive cognitive deficits due to accumulating
white matter hyperintensities due to cerebral small vessel
disease, although both clinical phenotypes are due to
VCID and may have shared mechanistic pathways. To
date, the challenge has been to come up with diagnostic con-
structs that are broad enough to capture the full spectrum of
VCID, yet also specific enough to classify targetable disease
processes within the VCID spectrum.
To address this challenge, biomarker frameworks of dis-
ease classification are being developed in a number of fields,
including pathological AD and VCID [15–17]. There is
strong evidence that AD pathology often coexists with
cerebrovascular disease with many risk factors being
shared, resulting in additive or synergistic effects on
cognitive decline [4]. Thus, biomarkers that inform VCID
pathology and etiology during life can have a major impact
across a number of diseases. Possibly, the ways forward are
approaches similar to those currently seen in the AD field
where the “clinical syndrome” and the pathology, although
clearly interrelated, are defined separately [15].
In this light, biomarker development has been a key
area of interest in VCID research. The use of biomarkers
in basic and clinical research as well as in clinical practice
has become a commonplace occurrence. Biomarkers are
needed in all areas of research, including clinical research,
clinical trials, and care settings, and a biomarker validated
Fig. 1. VCID bibliometric topic map. Research topics are based on the results of the Latent Dirichlet Analysis (LDA) algorithm. LDAworks by first creating a
set of term vocabularies for each of a prespecified number of topics based on the terms’ co-occurrence in publication abstracts. The algorithm then uses those
vocabularies to assign individual publications to one or more of these topics based on the frequency with which terms from that topic appear in the publication’s
abstract. Publications were pulled from PubMed using the following search string: (((dementia OR (cognitive impairment) OR (cognitive dysfunction)) AND
(vascular OR cardiovascular OR cerebrovascular OR lacunar OR stroke)) OR CADASILOR (cerebral autosomal dominant arteriopathy) OR (Binswanger[tiab]
OR Binswanger’s[tiab]) OR (cerebral amyloid angiopathy)) AND 2002:2016[dp]. For this analysis, the number of topics was set to 50, the algorithmwas run on
the publication abstracts in this data set. A topic similarity network was generated in which topics are connected if more than 45 articles in the data set were
assigned to both of the connected topics. Descriptions were assigned to each topic based on the abstract and MeSH terms that most frequently appeared in each
topic and on manual inspection of the papers assigned to each topic.
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applicable. In many cases, however, the validity of bio-
markers still needs to be evaluated and, at times, reeval-
uated as our understanding of the diseases and the uses
of the biomarker are considered [18]. In VCID, bio-
markers are often focused on imaging (e.g., brain or other
tissue such as the retina) and fluid-based (e.g., blood,
plasma, serum, urine, and cerebral spinal fluid). The char-
acteristics they capture and measure, such as downstream
tissue injury or actual disease processes, determine their
clinical and scientific utility. After biomarkers have been
well validated, they can be appropriately used by the
research and medical communities. The advancement of
the science of VCID toward therapeutic treatment is
also enhanced by consortia that are more focused on foun-
dational discoveries on the mechanistic underpinnings of
VCID and on working to find ways to correct the biolog-
ical imbalance.
New medicines are identified through a process that in-
volves a wide range of scientific disciplines, including
several basic science disciplines (e.g., but not limited to:vascular biology, metabolism, immunology, biochemistry,
chemistry, and pharmacology), as well as a diverse spectrum
of clinical sciences ranging from clinical stroke through
clinical cognitive impairment and dementia, and related
relevant disciplines. VCID consortia around the world are
working to identify targets and are moving them out of the
preclinical discovery phase and through the drug discovery
process.
Research consortia offer the unique ability to move a
basic mechanism and clinical finding forward by address-
ing barriers, such as the traditional silos between basic
researcher and clinical researcher, and providing a diverse
set of scientific perspectives to a single problem. A single
consortium can work with molecular information gained
from the basic science and use clinical samples to study
diagnosis, expression of disease biomarkers, differences
between normal and disease states, and response to ther-
apy. The multidisciplinary nature of the group is more
likely to allow for easy application of what is learned to
move a basic mechanistic observation to a clinical
discovery.
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VCID consortia discussed here are focused on multidisci-
plinary approaches to identify key pathologic targets and
develop diagnostic or prognostic tools with the goal of
bridging the divide between basic research and clinical tri-
als. The criteria used to identify these consortia are as fol-
lows: (1) pursuing the science of VCID; (2) multi-institute,
multidisciplinary teams; (3) identifying treatable etiological
targets; and/or developing biomarkers for use in clinical tri-
als (e.g., diagnosis, patient stratification, disease progres-
sion, target engagement, and prognosis). The primary
purpose of this review is to bring together information about
these consortia, summarized in Table 1, as a resource that
will help both inform and further facilitate the science of
VCID, with a particular focus on etiology and treatable tar-
gets with the potential to decrease disease burden.
Stroke affects people differently, with recovery from
stroke involving changes that can be debilitating and vary
from person to person in the physical, social, cognitive,
and emotional aspects of life. For this reason, poststroke
VCID is an active area of study. The Stroke and Cognition
Consortium (STROKOG), developed under the auspices of
Society for the Study of Vascular Cognitive and Behavioral
Disorders (VASCOG), brings together international longitu-
dinal cohort studies of cognitive decline and dementia after
stroke or TIA. The goals of the consortium are to facilitate a
better understanding of the determinants and manifestations
of vascular contributions to cognitive disorders and to
improve the diagnosis and treatment of VCID [19]. An addi-
tional key objective is to harmonize shared, nonidentifiable
data from member studies and perform individual partici-
pant data meta-analyses. Studies in the consortium have
examined poststroke or other high vascular risk cohorts
longitudinally, with cognitive decline, including dementia,
as primary outcome variables. As of April 2019, the con-
sortium has 32 member studies, and in total, this includes
approximately 18,000 enrolled individuals from 18 coun-
tries.
Another consortium focused on stroke and cognition, the
International Stroke Genetics Consortium (ISGC), was
launched in April 2007 at the Annual Meeting of the Amer-
ican Academy of Neurology. The initial aim was to bring
together resources and expertise to advance research on
stroke genomics. This has evolved toward broader goals of
advancing research on the biological mechanisms underly-
ing stroke risk, stroke severity, and consequences of stroke,
such as cognitive and functional outcomes. The consortium
has diversified its activities, broadening the scope to encom-
pass not only genomics but also other ‘omics’ approaches, as
well as translational studies. Extensive research is also con-
ducted to better understand the genetic underpinnings of
imaging-based stroke endophenotypes, especially MRI
markers of cerebral small vessel disease, and the impact of
these on VCID. Participating studies are both clinic-based
and population-based (in collaboration with the Cohortsfor Heart and Aging Research in Genomic Epidemiology
[CHARGE] consortium), including large biobanks [20–22].
The MarkVCID consortium has a translational focus by
aiming to deliver discrete high-quality biomarker kits ready
for use in clinical trials by developing and validating bio-
markers for small vessel VCID [23]. Diseases of the brain’s
network of small blood vessels, most prominently arteriolo-
sclerosis and cerebral amyloid angiopathy, have also been
shown to be major contributors to cognitive impairment
and dementia. These small-vessel disease pathologies often
overlap with other conditions such as clinical and patholog-
ical AD. The mission of the consortium is to analyze and
optimize candidate VCID biomarkers and participate in a
consortium-wide program of biomarker scaling-up, multi-
site protocol implementation, and multisite validation with
discrete biomarker kits emerging at the end of the process
that can be moved to large scale validation and handed off
to clinical trials in the future [24].
A novel trans-Atlantic VCID consortium funded by the
Fondation Leducq is called Understanding the Role of the
Perivascular Space in Cerebral Small Vessel Disease. This
consortium is using parallel studies in humans who had
stroke stroke or cognitive presentations of small vessel dis-
eases, and a corresponding range of representative labora-
tory models, with harmonized protocols for human and
rodent MRI to pursue the hypothesis that small-vessel
VCID–associated brain injury is related to structural
changes in and dysfunction of the perivascular space and
that a better understanding of the perivascular space and
small vessel VCID interactions, including pathology, will
result in the identification of novel therapeutic targets [25].
SVDs@target brings together basic scientists and clini-
cians to make use of novel animal models, technologies,
and expertly phenotyped patient cohorts. The consortium’s
aim is to identify key mechanisms common to multiple
small-vessel diseases that are relevant to VCID and to vali-
date these novel mechanisms through manipulations in
model systems and interventions in human subjects, with
the ultimate goal of reducing the burden of VCID. A key
feature of this program is that it combines and leverages
both preclinical and clinical research toward its applied
goals in VCID.
Understanding the relationship among diseases of the
heart, blood vessels, and brain is an emerging scientific
area that is highly relevant to VCID. The Heart-Brain
Connection is a Dutch interdisciplinary network with ori-
gins that lie in studies of hemodynamic changes in VCID
that is in part motivated by the AHA/ASA and the Na-
tional Plan to Address Alzheimer’s Disease research pri-
orities. With the goal of identifying new strategies for
prevention and treatment of VCID, this consortium pur-
sues comprehensive animal research and diagnostic hospi-
tal- and population-based studies to increase the
understanding of the mechanisms involved in linking car-
diovascular and cognitive dysfunction. This consortium
will also develop new tools that, combined with new
Table 1
Detailed Information about VCID consortia
Name
Date
founded Location(s)
Current
leadership Funding Website
Understanding
the role of the
perivascular
space in cerebral
small-vessel
disease
2017 United
Kingdom,
Denmark,
France,
Germany,
North
America:
United States
of America,
Canada
European
Coordinator:
Joanna M
Wardlaw,
North
American
Coordinator:
Berislav
Zlokovic
Fondation Leducq
Transatlantic
Network
of Excellence
https://www.fondationleducq.org/network/
understanding-the-role-of-the-perivascu
lar-space-in-cerebral-small-vessel-disease/
Stroke and
Cognition
Consortium
(STROKOG)
2015 Europe: United
Kingdom,
Poland,
the Netherlands,
Scotland, Ireland,
France, Germany,
Finland, Sweden,
Bulgaria, Asia:
Korea, Singapore,
China, Hong Kong,
North America:
United States of
America, Africa:
South Africa,
Nigeria, Australia:
Australia
Consortium
Leader:
Professor
Perminder
Sachdev
National Health &
Medical
Research Council
(NHMRC)
(Australia),
The Dementia
Momentum
fund from
the Center of
Healthy
Brain Aging
(CHeBA),
UNSW
Medicine,
University
of New South
Wales,
and the Vincent
Fairfax
Family
Foundation.
https://cheba.unsw.edu.au/group/strokog
Biomarkers
for Vascular
Contributions
to Cognitive
Impairment
and Dementia
Consortium
(MarkVCID)
2016 North America:
United States
of America
Coordinating
Center:
Dr. Steven
M. Greenberg Sites:
Dr. Hanzhang Lu,
Dr. Danny J. J. Wang,
Dr. Sudha Seshadri,
Dr. Gary A. Rosenberg,
Dr. Julie A. Schneider,
Dr. Joel H. Kramer,
Dr. Donna M. Wilcock
NINDS/NIA/NIH https://markvcid.partners.org/
SVDs@target 2016 Europe:
Germany,
the United
Kingdom,
the Netherlands
Leader consortium:
Prof. Martin
Dichgans, Leader
clinical study
Zoom@SVDs:
Prof. Geert Jan
Biessels,
Leader clinical
study INVESTIGATE-
SVDs:
Prof. Joanna Wardlaw,
Leader clinical trial
TREAT-SVDs:
Prof. Martin Dichgans
European Union’s
Horizon 2020
research
and innovation
programme under
grant agreement
No. 666881
https://www.svds-at-target.eu/
(Continued )
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Table 1
Detailed Information about VCID consortia (Continued )
Name
Date
founded Location(s)
Current
leadership Funding Website
The Heart-Brain
Connection:
the missing
link in the
pathophysiology
of vascular
cognitive
impairment
(HBC)
2013 Europe:
Netherlands
Current program leaders:
Prof. Dr. M. J. Daemen,
Prof. Dr. G. J. Biessels,
Past program leader:
Prof. Dr. M. A. van
Buchem
Dutch Heart
Foundation
http://www.heart-brain.nl/
International
Stroke
Genetics
Consortium
(ISGC)
2007 Members
come from
all continents
and more
than 30
countries
Chair: Dr. Stephanie
Debette, Vice Chair:
Dr. Jin-Moo Lee,
Immediate Past Chair:
Dr. Daniel Woo
Founded:
Dr. Jonathan Rosand
Registration fees
for workshops,
private
donations
(for travel
scholarships,
prizes,
workshop
proceedings,
website etc.),
and project-
specific
grants
http://www.strokegenetics.org/
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personalized therapeutic options to improve or stabilize
declining cognition.2. Conclusion
The NIH officially recognized the science of VCID by
starting to track spending on VCID research in NIH Re-
porter, aligning the acronym with “vascular cognitive
impairment/dementia.” Investment in VCID research has
risen from $45M when tracking began in 2014 to
$259M in 2018 [26]. Funding of VCID research has
also increased internationally because investigators, the
public, and funding agencies increasingly recognize its
public health impact and synergy at the intersection of
stroke and dementia, two of the most pressing health is-
sues around the world [27].
Although the multidisciplinary research of VCID science
continues to expand our understanding of cellular and mo-
lecular mechanisms, the scope and complexity of VCID pa-
thologies and clinical syndromes continue to present large
challenges to translating basic science findings into the
clinic. Here, we have described how six consortia are work-
ing to address this bottleneck and to improve our ability to
diagnose and treat VCID.Many of these efforts include large
cohorts of human subjects that also act as resources for other
researchers who want to address the science of VCID. The
NIH, led by the NINDS, NHLBI, and NIA, has identified
such VCID cohorts (https://www.ninds.nih.gov/Current-
Research/Focus-Disorders/VCID-Cohorts-Tool), although
this represents only a partial list of all of the human-basedVCID efforts around the world. The multinational Joint Pro-
gramme for Neurodegenerative Diseases have funded efforts
to catalog (https://www.neurodegenerationresearch.eu/
jpnd-global-cohort-portal/) completed and ongoing popu-
lation and cohort observational studies and clinical trial
data sets with data relevant to vascular cognitive impairment
that are available for secondary analyses and meta-analyses
and also created a searchable portal hosting studies relevant
to neurodegenerative disease research including VCID [28].
In addition to the consortia and cohort efforts mentioned in
this study, there are many other international collaborative
activities aimed at understanding, diagnosing, or amelio-
rating the effects of VCID, including the Joint Programme
for Neurodegenerative Diseases–funded HARNESS initia-
tive (https://harness-neuroimaging.org/) to disseminate stan-
dardized image acquisition and analysis tools to advance
research in the field [10]. Furthermore, there is ample scien-
tific space and need for new VCID consortia and cohorts to
move the community forward. By increasing multidisci-
plinary collaboration, including researchers with diverse sci-
entific backgrounds and perspectives, the biomedical
community can begin to address the significant public-
health burden associated with this heterogeneous group of
conditions.Acknowledgments
The authors thank all the consortium members and staff who
contributed to the efforts mentioned in this manuscript and
assisted in providing background material.
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1. Systematic review: The Criteria used to identify
these consortia are as follows: (1) pursuing the sci-
ence of VCID; (2) multi-institute, multidisciplinary
teams; (3) identifying treatable etiological targets;
and/or developing biomarkers for use in clinical tri-
als. Once identified the consortia leads were invited
to provide a description of their efforts.
2. Interpretation: The review brings together informa-
tion about multiple consortia as a resource that will
help both inform and further facilitate the science
of VCID, with a particular focus on etiology and
treatable targets with the potential to decrease dis-
ease burden.
3. Future directions: The consortia discussed in this
article, and others like them, are uniquely suited to
tackle some of the most difficult obstacles in trans-
lating research to the clinic. Over the next years, as
the research efforts of these consortia continue, we
will see advances in identifying key pathologic tar-
gets and developing diagnostic or prognostic tools.References
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